103 related articles for article (PubMed ID: 15572539)
21. [The temporal and spatial distribution of vasoactive intestinal peptide and its receptor in the development of airway hyperresponsiveness].
Ren YH; Qin XQ; Guan CX; Luo ZQ; Zhang CQ; Sun XH
Zhonghua Jie He He Hu Xi Za Zhi; 2004 Apr; 27(4):224-8. PubMed ID: 15144609
[TBL] [Abstract][Full Text] [Related]
22. Immunocytochemical identification of VPAC1, VPAC2, and PAC1 receptors in normal and neoplastic human tissues with subtype-specific antibodies.
Schulz S; Röcken C; Mawrin C; Weise W; Höllt V; Schulz S
Clin Cancer Res; 2004 Dec; 10(24):8235-42. PubMed ID: 15623599
[TBL] [Abstract][Full Text] [Related]
23. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension.
Petkov V; Mosgoeller W; Ziesche R; Raderer M; Stiebellehner L; Vonbank K; Funk GC; Hamilton G; Novotny C; Burian B; Block LH
J Clin Invest; 2003 May; 111(9):1339-46. PubMed ID: 12727925
[TBL] [Abstract][Full Text] [Related]
24. Ageing and the diurnal expression of mRNAs for vasoactive intestinal peptide and for the VPAC2 and PAC1 receptors in the suprachiasmatic nucleus of male rats.
Kalló I; Kalamatianos T; Piggins HD; Coen CW
J Neuroendocrinol; 2004 Sep; 16(9):758-66. PubMed ID: 15344914
[TBL] [Abstract][Full Text] [Related]
25. Expression of mRNAs for PACAP and its receptor in human neuroblastomas and their relationship to catecholamine synthesis.
Isobe K; Kaneko M; Kaneko S; Nissato S; Nanmoku T; Takekoshi K; Okuda Y; Kawakami Y
Regul Pept; 2004 Dec; 123(1-3):29-32. PubMed ID: 15518890
[TBL] [Abstract][Full Text] [Related]
26. Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: evidence for multiple receptor states.
Van Rampelbergh J; Gourlet P; De Neef P; Robberecht P; Waelbroeck M
Mol Pharmacol; 1996 Dec; 50(6):1596-604. PubMed ID: 8967982
[TBL] [Abstract][Full Text] [Related]
27. Inhibition by vasoactive intestinal peptide of glycoconjugate and lysozyme secretion by human airways in vitro.
Coles SJ; Said SI; Reid LM
Am Rev Respir Dis; 1981 Nov; 124(5):531-6. PubMed ID: 7305106
[TBL] [Abstract][Full Text] [Related]
28. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide stimulate interleukin-6 production in prostate cancer cells and prostatic epithelial cells.
Nagakawa O; Junicho A; Akashi T; Koizumi K; Matsuda T; Fuse H; Saiki I
Oncol Rep; 2005 Jun; 13(6):1217-21. PubMed ID: 15870945
[TBL] [Abstract][Full Text] [Related]
29. Human H9 cells proliferation is differently controlled by vasoactive intestinal peptide or peptide histidine methionine: implication of a GTP-insensitive form of VPAC1 receptor.
Goursaud S; Pineau N; Becq-Giraudon L; Gressens P; Muller JM; Janet T
J Neuroimmunol; 2005 Jan; 158(1-2):94-105. PubMed ID: 15589042
[TBL] [Abstract][Full Text] [Related]
30. Long-acting analogue of vasoactive intestinal peptide, [R15, 20, 21, L17]-VIP-GRR (IK312532), protects rat alveolar L2 cells from the cytotoxicity of cigarette smoke.
Onoue S; Endo K; Ohmori Y; Yamada S; Kimura R; Yajima T; Kashimoto K
Regul Pept; 2004 Dec; 123(1-3):193-9. PubMed ID: 15518912
[TBL] [Abstract][Full Text] [Related]
31. Temporal and spatial distribution of VIP, CGRP and their receptors in the development of airway hyperresponsiveness in the lungs.
Ren YH; Qin XQ; Guan CX; Luo ZQ; Zhang CQ; Sun XH
Sheng Li Xue Bao; 2004 Apr; 56(2):137-46. PubMed ID: 15127121
[TBL] [Abstract][Full Text] [Related]
32. Vasoactive intestinal peptide receptor expression in chronic periapical lesions.
Caviedes-Bucheli J; Azuero-Holguín MM; Moreno GC; González IL; Mateu E; Salazar JF; Munoz HR
Int Endod J; 2007 Jul; 40(7):521-5. PubMed ID: 17511789
[TBL] [Abstract][Full Text] [Related]
33. The distribution of neurokinin-1 and neurokinin-2 receptors in human central airways.
Mapp CE; Miotto D; Braccioni F; Saetta M; Turato G; Maestrelli P; Krause JE; Karpitskiy V; Boyd N; Geppetti P; Fabbri LM
Am J Respir Crit Care Med; 2000 Jan; 161(1):207-15. PubMed ID: 10619822
[TBL] [Abstract][Full Text] [Related]
34. Site-directed mutagenesis of human vasoactive intestinal peptide receptor subtypes VIP1 and VIP2: evidence for difference in the structure-function relationship.
Nicole P; Du K; Couvineau A; Laburthe M
J Pharmacol Exp Ther; 1998 Feb; 284(2):744-50. PubMed ID: 9454823
[TBL] [Abstract][Full Text] [Related]
35. Distribution of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors (VPAC1, VPAC2, and PAC1 receptor) in the rat brain.
Joo KM; Chung YH; Kim MK; Nam RH; Lee BL; Lee KH; Cha CI
J Comp Neurol; 2004 Aug; 476(4):388-413. PubMed ID: 15282712
[TBL] [Abstract][Full Text] [Related]
36. Expression of protease activated receptor-2 (PAR-2) in central airways of smokers and non-smokers.
Miotto D; Hollenberg MD; Bunnett NW; Papi A; Braccioni F; Boschetto P; Rea F; Zuin A; Geppetti P; Saetta M; Maestrelli P; Fabbri LM; Mapp CE
Thorax; 2002 Feb; 57(2):146-51. PubMed ID: 11828045
[TBL] [Abstract][Full Text] [Related]
37. VIP enhances synaptic transmission to hippocampal CA1 pyramidal cells through activation of both VPAC1 and VPAC2 receptors.
Cunha-Reis D; Ribeiro JA; Sebastião AM
Brain Res; 2005 Jul; 1049(1):52-60. PubMed ID: 15935995
[TBL] [Abstract][Full Text] [Related]
38. Coronary vascular effects of vasoactive intestinal peptide in the isolated perfused rat heart.
Sawmiller DR; Henning RJ; Cuevas J; Dehaven WI; Vesely DL
Neuropeptides; 2004 Oct; 38(5):289-97. PubMed ID: 15464194
[TBL] [Abstract][Full Text] [Related]
39. Expression and function of vasoactive intestinal peptide receptors in human lower esophageal sphincter.
Jia T; Zhao N
Ann Palliat Med; 2021 Mar; 10(3):3067-3077. PubMed ID: 33849096
[TBL] [Abstract][Full Text] [Related]
40. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation.
Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
J Immunol; 1999 Apr; 162(8):4685-96. PubMed ID: 10202009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
